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Epidemiology, Co-Infections, and Outcomes of Viral
Pneumonia in Adults
An Observational Cohort Study
Matthew P. Crotty, PharmD, Shelby Meyers, Nicholas Hampton, PharmD, Stephanie Bledsoe,
David J. Ritchie, PharmD, Richard S. Buller, PhD, Gregory A. Storch, MD,
Scott T. Micek, PharmD, and Marin H. Kollef, MD
Abstract: Advanced technologies using polymerase-chain reaction
have allowed for increased recognition of viral respiratory infections
including pneumonia. Co-infections have been described for several
respiratory viruses, especially with influenza. Outcomes of viral
pneumonia, including cases with co-infections, have not been well
described.
This was observational cohort study conducted to describe hos-
pitalized patients with viral pneumonia including co-infections,
clinical outcomes, and predictors of mortality. Patients admitted from
March 2013 to November 2014 with a positive respiratory virus panel
(RVP) and radiographic findings of pneumonia within 48 h of the
index RVP were included. Co-respiratory infection (CRI) was defined
as any organism identification from a respiratory specimen within 3
days of the index RVP. Predictors of in-hospital mortality on uni-
variate analysis were evaluated in a multivariate model.
Of 284 patients with viral pneumonia, a majority (51.8%) were
immunocompromised. A total of 84 patients (29.6%) were found to
have a CRI with 48 (57.6%) having a bacterial CRI. Viral CRI with
HSV, CMV, or both occurred in 28 patients (33.3%). Fungal (16.7%)
and other CRIs (7.1%) were less common. Many patients required
mechanical ventilation (54%) and vasopressor support (36%). Overall
in-hospital mortality was high (23.2%) and readmissions were com-
mon with several patients re-hospitalized within 30 (21.1%) and 90
days (36.7%) of discharge. Predictors of in-hospital mortality on
multivariate regression included severity of illness factors, stem-cell
transplant, and identification of multiple respiratory viruses. In con-
clusion, hospital mortality is high among adult patients with viral
pneumonia and patients with multiple respiratory viruses identified
may be at a higher risk.
(Medicine 94(50):e2332)
Abbreviations: APACHE = Acute Physiology and Chronic Health
Evaluation, CMV = cytomegalovirus, CRI = co-respiratory
infection, eMR = electronic medical record, hMPV = human
metapneumovirus, HSV = herpes simplex virus, ICU = intensive
care unit, LOS = length-of-stay, NP = nasopharyngeal, PIV =
parainfluenza virus, RCI = respiratory co-infection, RSV =
respiratory syncytial virus, RVP = respiratory virus panel.
INTRODUCTION
V iral pneumonia and lower respiratory tract infections areincreasingly being recognized in adult patients including
the critically ill.1,2 It appears that most viral lower respiratory
tract infections are community-acquired and account for a
significant etiology in mechanically ventilated patients
with severe community-acquired pneumonia.3,4 Bacterial-
viral co-infections are best described with influenza. The
long history of bacterial infections occurring concurrently or
shortly after influenza illness dates back to the 1918 influ-
enza pandemic in which most of the fatal cases were found to
be due to co-infection based on autopsy findings.5 More
recently the 2009 H1N1 influenza pandemic was complicated
by bacterial pneumonia in 4% to 33% of hospitalized or
critically ill patients.6–11 Most commonly isolated co-infect-
ing bacterial organisms with influenza are Streptococcus
pneumoniae, Staphylococcus aureus, S. pyogenes, and
Haemophilus influenzae. Influenza seasons are not equal
as some are associated with lower mortality potentially
related to differences in virulence factors or other unknown
reasons.12–15
Bacterial co-infection is not limited to influenza and has
been described with numerous other respiratory viruses,
including respiratory syncytial virus (RSV), parainfluenza
virus (PIV), rhinovirus, adenovirus, and human metapneumo-
virus (hMPV).16–25Advanced technologies have allowed for
increased recognition of viral pathogens and diagnoses of viral
respiratory infections including pneumonia.26 Several mech-
anisms by which viral respiratory infections may predispose
patients to bacterial co-infections have been investigated
including virus-induced alterations in epithelial cells,
impaired immune response, and enhanced bacterial coloniza-
tion.27 Utilizing new diagnostic technologies, it may be
possible to better describe the clinical aspects of viral pneu-
monia and interactions with other infecting organisms. The
purpose of this study was to describe hospitalized adult
patients with viral pneumonia including possible co-infections
and clinical outcomes.
Editor: Krisztian Banyai.
Received: October 28, 2015; revised: November 12, 2015; accepted:
November 27, 2015.
From the Pharmacy St. Louis College of Pharmacy (STLCOP) (MPC);
STLCOP and Dept of Pharmacy, Barnes-Jewish Hospital (DJR); STLCOP
(SM); STLCOP and Dept of Pharmacy, Barnes-Jewish Hospital (STM);
Center for Clinical Excellence, BJC Healthcare (NH); Department of
Pediatrics, Washington University School of Medicine (RSB, GAS); and
Division of Pulmonary and Critical Care Medicine, Washington University
School of Medicine (MHK).
Correspondence: Marin H. Kollef, Division of Pulmonary and Critical Care
Medicine Washington University School of Medicine 4523 Clayton
Avenue, Campus Box 8052, St. Louis, MO (e-mail: mkollef@dom.
wustl.edu).
Funding: Dr. Kollef’s effort was supported by the Barnes-Jewish Hospital
Foundation.
All authors have declared no competing interests.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
This is an open access article distributed under the Creative Commons
Attribution License 4.0, which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
ISSN: 0025-7974
DOI: 10.1097/MD.0000000000002332
Medicine®
OBSERVATIONAL STUDY
Medicine  Volume 94, Number 50, December 2015 www.md-journal.com | 1
METHODS
Subjects and Study Design
This was a single-center, observational cohort study of
patients with a positive respiratory virus panel (RVP) at Barnes-
Jewish Hospital (a 1300-bed urban academic medical center in
St. Louis, MO) between 1 March 2013 and 7 November 2014.
The study protocol was approved by the Barnes-Jewish Hospi-
tal, Washington University and St. Louis College of Pharmacy
Institutional Review Boards. Adult patients (19 years of age)
admitted to the hospital for >24 h were identified through a
query of an internal database, which tracks respiratory viruses
and evaluated for study inclusion. Patients were excluded if no
virus was identified by RVP, rhinovirus or enterovirus was
identified by nasopharyngeal (NP) swab only, or if a respiratory
virus had been identified within the 90 days before the
index RVP.
Respiratory Virus Panel
The FilmArray1 respiratory panel assay (BioFire Diag-
nostics, Salt Lake City, UT) is a multiplex nucleic acid test
capable of simultaneous qualitative detection and identification
of multiple respiratory viral and bacterial nucleic acids. This
panel became the primary diagnostic RVP used at BJH inMarch
of 2013 and is capable of detecting 20 total respiratory patho-
gens (17 viral and 3 bacterial): Bordetella pertussis, Chlamy-
dophilapneumoniae, Mycoplasma pneumoniae, Adenovirus,
Coronavirus HKU1, Coronavirus NL63, Coronavirus 229E,
Coronavirus OC43, Influenza A, Influenza A subtype H1,
Influenza A subtype H3, Influenza A subtype 2009 H1, Influ-
enza B, hMPV, PIV 1, PIV 2, PIV 3, PIV 4, RSV, and rhinovirus/
enterovirus. The assay cannot reliably differentiate between
human rhinovirus and enterovirus due to their genetic similarity.
The FilmArray1 respiratory panel assay is FDA approved
for NP swabs and additional sample types have been
validated internally.
DEFINITIONS
Viral pneumonia was defined as identification of a respir-
atory virus by RVP and a new or progressive radiographic
infiltrate within 48 h. Respiratory co-infection (RCI) was
defined as identification of a respiratory pathogen from a
specimen obtained within 72 h of the index RVP. RCIs were
stratified as bacterial, viral (HSV or CMV), fungal, or other
RCI, which included Mycobacteria spp. and Pneumocystis
jiroveci. Candida spp. isolated from respiratory specimens were
excluded from RCI consideration. Immunocompromised status
was defined as a diagnosis of HIV, active malignancy (stem cell
transplant or receiving chemotherapy), solid organ transplant,
or currently receiving immunosuppressive therapy (prednisone
20mg/day for at least 30 days or equivalent). Determination of
APACHE II scores was based on physical and laboratory
findings on the day the index RVP was obtained. Charlson’s
comorbidity index was used as a summative score of underlying
disease states.28 Electronic medical record (eMR) queries were
used to acquire patient information where possible. Manual
chart review was used to validate and supplement all
eMR queries.
Microbiologic Evaluation
Information regarding RVPs including time of collection/
report, type of specimen, patient location at time of collection,
and resulting findings were obtained from an internal database.
Additionally, all available aerobic and anaerobic bacterial
cultures were evaluated as available based on eMR query. Urine
antigens for Legionella, direct-fluorescent antibody for Pneu-
mocystis jiroveci, andClostridium difficile toxin assay were also
evaluated. In vitro susceptibilities were evaluated as reported
per institutional practices.
Endpoints
The primary endpoint evaluated was in-hospital mortality.
Secondary endpoints included hospital length-of-stay (LOS),
intensive care unit (ICU) admission, and readmission rates at
30, 90, and 180 days after the index hospitalization.
Statistical Analysis
Descriptive statistics were used to describe the overall
population of adult patients with viral pneumonia. Univariate
analyses were then performed to compare survivors and non-
survivors. Categorical variables were compared using chi
square or Fisher’s exact test as appropriate. Continuous vari-
ables were compared using the Mann–Whitney U test. All tests
were 2-tailed and P values <0.05 were considered significant.
Multivariable logistic regression analysis was then used to
determine factors independently associated with in-hospital
mortality. Variables with P values<0.20 on univariate analyses
were entered into a multivariable model using a backward
stepwise approach. All statistical analyses were performed
using SPSS (version 22.0; Chicago, IL).
RESULTS
Study Population and Patient Characteristics
A total of 284 adult patients were identified as having viral
pneumonia in this study (Fig. 1). Demographics and clinic
characteristics are summarized in Table 1. There were slightly
more women than men and most patients were Caucasian
(66.9%). A majority of patients were immunocompromised
(51.8%) with active malignancy (64.6%) the most common
etiology followed by solid organ transplant (23.1%). Nearly all
patients had at least 1 chronic comorbid condition (84.2%) with
several having >1 (47.9%). Diabetes mellitus, chronic kidney
disease, and chronic obstructive pulmonary disease were the
most commonly identified comorbid conditions. Few patients
had been hospitalized in the 90 days prior to the index admission
(3.2%).
Most patients were critically ill (69.4%) with severity of
illness also very high as illustrated by the median APACHE II
score of 16. A majority of patients were mechanically ventilated
(53.9%) and several required vasopressor support (35.9%).
Virus Identification
The most common viruses identified were influenza
(24.3%), rhinovirus or enterovirus (23.6%), PIV (13%), and
RSV (10.6%) (Table 2). Several (n¼ 14) patients had multiple
viruses identified by RVP (Fig. 2). RSV (50%), rhinovirus/
enterovirus (50%), influenza (28.6%) and coronavirus (28.6%)
were most commonly identified among patients with multiple
viruses identified by RVP. Most patients with multiple viruses
were immunocompromised (10 of 14): 6 with active malig-
nancy (4 with stem-cell transplants), 3 with lung transplants,
and 1 patient with AIDS. Among the 73 patients with influenza,
56.2% (n¼ 41) received oseltamivir and 16.4% (n¼ 12)
received investigational intravenous zanamivir. Inhaled riba-
virin was administered to 21.6% (n¼ 8) of patients with RSV
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and 4.6% (n¼ 13) of patients overall. Other indications for
inhaled ribavirin included hMPV, PIV, and rhinovirus/enter-
ovirus.
Respiratory Co-infections
A total of 84 (29.6%) of patients with viral pneumonia had
an identified RCI with bacterial co-infection (57.1%) being
most common (Table 3). Patients with adenovirus or multiple
viruses identified by RVP were most likely to have a bacterial
RCI (Fig. 3). Patients with viral pneumonia due to PIV, RSV, or
influenza were least likely to have a bacterial RCI. Only 1.1%
(n¼ 3) patients went on to have a subsequent bacterial RCI with
all occurring 4 to 7 days after the index RVP report date. One-
third of patients (n¼ 28) with an RCI had either HSV or CMV
co-infection. Patients with adenovirus pneumonia were most
likely to have CMV RCI. Rates of CMV RCI did not differ
much among the other RVP virus types. A total of 14 patients
(4.9%) had an identified fungal RCI, 50% (n¼ 7) were immu-
nocompromised with 36% (n¼ 5) having active malignancy.
Aspergillus sp. were the most common fungal organisms seen
Abbreviations.R/E: rhinovirus/enterovirus; NP: nasopharyngeal; RVP: respiratory virus panel.
RVP positive episodes screened
(n=1018)
Excluded (n=923)
R/E identified from NP swab only (n=243) 
(n=216)Repeat RVP within 90 days of initial  
No radiographic findings of pneumonia (n=183)
Not admitted for at least 24 hours (n=88)
Episodes of viral pneumonia
(n=284) 
FIGURE 1. Identification of study population.
TABLE 1. Demographic and Clinical Characteristics of Adult
Patients With Viral Pneumonia
n (%) All Patients (N¼ 284)
Age, meanSD 54.5 16.03
Female 148 (52.1)
Caucasian 190 (66.9)
African American 77 (27.1)
Weight-kg, median (IQR) 80.1 (63.5–102)
Prior admit within 90 days 9 (3.2)
Chronic heart failure 44 (15.5)
Coronary artery disease 48 (15.8)
COPD 61 (21.5)
Diabetes mellitus 89 (31.3)
Chronic kidney disease 60 (21.1)
ESRD on HD 18 (6.3)
Cirrhosis 8 (2.8)
Cystic fibrosis 7 (2.5)
Human immunodeficiency virus 6 (2.1)
Active malignancy 95 (33.5)
Stem cell transplant 37 (13.0)
Solid organ transplant 34 (12.0)
Lung 19 (6.7)
Heart 5 (1.8)
Kidney 10 (3.5)
Liver 1 (0.4)
Immunosuppressive therapy 18 (6.3)
Immunocompromised 147 (51.8)
CCI, median (IQR) 5 (3–7)
Intensive care unit admit 197 (69.4)
Oncology

58 (20.4)
Nononcology 139 (48.9)
Mechanical ventilation 153 (53.9)
Days, median (IQR) 7.98 (3.3–16.1)
Hours, median (IQR) 191.5 (79.5–385.3)
Central line placed, n (%) 171 (60.2)
Vasopressor support, n (%) 102 (35.9)
Days, median (IQR) 5.85 (2.6–13.1)
Hours, median (IQR) 140.4 (61.4–314.9)
APACHE II, median (IQR) 16 (11–21)
APACHE¼Acute Physiology and Chronic Health Evaluation,
BMI¼ body mass-index, CCI¼Charlson’s comorbidity index,
COPD¼ chronic obstructive pulmonary disease, ESRD on HD¼ end-
stage renal disease on hemodialysis, IQR¼ interquartile range,
SD¼ standard deviation.
ICU admission was determined to be oncology-related if the patient
had active malignancy.
TABLE 2. Viruses Identified in Patients With Viral Pneumonia
n (%) All Patients (N¼ 284)
Influenza 69 (24.3)
Rhinovirus/enterovirus 67 (23.6)
PIV 37 (13.0)
RSV 30 (10.6)
Coronavirus 26 (9.2)
hMPV 25 (8.8)
Adenovirus 16 (5.6)
Multiple viruses 14 (4.9)
RSV 7/14 (50)
Rhinovirus/enterovirus 7/14 (50)
Influenza 4/14 (28.6)
Coronavirus 4/14 (28.6)
hMPV 3/14 (21.4)
Adenovirus 2/14 (14.3)
PIV 2/14 (14.3)
hMPV¼ human metapneumovirus, PIV¼ parainfluenza, RSV¼
respiratory syncytial virus.
Patient ADV CRV IFV hMPV PIV R/E RSV
1 X X
2 X X X
3 X X
4 X X
5 X X
6 X X
7 X X
8 X X
9 X X
10 X X
11 X X
12 X X
13 X X
14 X X
Abbreviations. ADV: adenovirus; CRV: coronavirus; IFV: influenza; hMPV: human metapneumovirus; PIV: 
parainfluenza; R/E: rhinovirus/enterovirus; RSV: respiratory syncytial virus
FIGURE 2. Description of patients with multiple respiratory
viruses identified.
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(50%; n¼ 7). Other fungi identified included Arthrographis sp.,
Bipolaris sp., Paecilomyces sp., Scedosporium sp., and Dema-
tiaceous fungi imperfecti. Fungal RCI rates were similar among
the different viruses identified by RVP. Few patients (1.8%;
n¼ 5) had mycobacterial RCI and only 1 patient (0.4%) had-
concomitant Pneumocystis jiroveci pneumonia identified.
Clinical Outcomes
The multivariate model used to evaluate in-hospital
mortality had an acceptable Hosmer–Lemeshow goodness-
of fit test (P¼ 0.837) and fit the data well with an area
under the receiver operating characteristic curve of 0.864
(Table 4). Variables identified as being associated with
in-hospital mortality included primarily severity of illness
factors: intensive care unit (ICU) admission, APACHE II
score, and vasopressor requirement. Stem-cell transplant
(aOR: 4.22; P¼ 0.004) and identification of multiple viruses
by RVP (aOR: 4.87; P¼ 0.038) were also associated
with mortality.
Overall in-hospital mortality was high (23.2%) with all but
1 patient being admitted to the ICU (98.5%). In-hospital
mortality was higher among ICU patients with active malig-
nancy compared to other ICU patients at 48.3% and 26.6%,
respectively (P¼ 0.003). ICU length-of-stay was variable
(median: 10.3 days; IQR: 4.4, 20.7) as was total hospital
length-of-stay (median: 12 days; IQR: 5, 25.75). Readmissions
were common with several patients re-hospitalized within 30
(21.1%) and 90-days (36.7%) of discharge.
DISCUSSION
This study described 284 hospitalized adult patients with
viral pneumonia and assessed factors associated with increased
in-hospital mortality. Identification of multiple viruses by RVP,
stem-cell transplant, ICU admission, APACHE II score, and
requirement of vasopressors were all significantly associated
with in-hospital mortality in a multivariable model. Several
patients (29.6%; n¼ 84) had RCIs with most being bacterial
(57.1%; n¼ 48). Patients with viral pneumonia due to adeno-
virus or multiple respiratory viruses were most likely to have a
bacterial RCI.
Increasing recognition of viruses as pathogens in lower
respiratory tract infections and pneumonia has altered the land-
scape of this illness. In our study, severity of illness charac-
teristics were identified as being the primary factors associated
with in-hospital mortality among patients with viral pneumonia.
TABLE 3. Respiratory Co-infections of Patients With Viral
Pneumonia
n (%) Any RCI (N¼ 84)
Bacterial RCI 48 (57.1)
Staphylococcus aureus 13 (15.5)
MRSA 9 (10.7)
Streptococci 5 (5.9)
Pseudomonas aeruginosa 4 (4.8)
Enterobacteriaceae 6 (7.1)
Enterobacter spp. 3 (3.6)
Haemophilus influenzae 2 (2.4)
Multiple bacteria 14 (16.7)
S. aureus 9 (10.7)
P. aeruginosa 4 (4.8)
Streptococci 4 (4.8)
Viral RCI 28 (33.3)
CMV 11 (13.1)
HSV 15 (17.9)
CMV and HSV 2 (2.4)
Fungal RCI 14 (16.7)
Aspergillus spp. 7 (8.3)
Other RCI 6 (7.1)
Mycobacteria 5 (6.0)
M. chelonae 2 (2.4)
M. avium-intracellulare 2 (2.4)
M. gordonae 1 (1.2)
Pneumocystis jiroveci 1 (1.2)
CCI¼Charlson’s comorbidity index, CMV¼ cytomegalovirus,
HSV¼Herpes simplex virus, ICU¼ intensive care unit,
MRSA¼methicillin-resistant Staphylococcus aureus, RCI¼ respira-
respiratory co-infection.
Abbreviations. hMPV: human metapneumovirus; PIV: parainfluenza; RCI: respiratory co-infection; R/E: 
rhinovirus/enterovirus.
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FIGURE 3. Respiratory co-infection rates according to virus
identified.
TABLE 4. Predictors of In-Hospital Mortality by Univariate and
Multivariate Logistic Regression

n (%)
Univariate
Analysis
Multivariate
Analysis P Value
OR P-value aOR 95% CI P Value
ICU admission 42.3 < 0.01 14.3 1.76, 116 0.01
Multiple Respiratory Viruses 2.63 0.08 4.87 1.09, 21.8 0.04
Stem-cell Transplant 2.62 0.01 4.22 1.57, 11.3 0.01
Vasopressors 6.05 <0.01 2.68 1.27, 5.64 0.01
APACHE II 1.16 <0.01 1.11 1.04, 1.18 0.01
Solid organ Transplant 0.287 0.03 0.28 0.07, 1.14 0.08
Fungal RCI 3.58 0.02 3.23 0.87, 12.0 0.08
Outside hospital Transfer 2.21 0.01 2.08 0.98, 4.44 0.06
RSV 1.72 0.16 – – –
Bacterial infection (Any) 1.79 0.04 – – –
CMV RCI 2.15 0.18 – – –
Mechanical Ventilation 5.41 < 0.01 – – –
CCI 1.16 0.01 – – –
aOR¼ adjusted odds ratio, APACHE¼Acute Physiology and Chronic Health
Evaluation, CCI¼Charlson’s comorbidity index, CI¼ confidence interval,
CMV¼ cytomegalovirus, ICU¼ intensive care unit, OR¼ odds ratio,
RCI¼ respiratory co-infection, RSV¼ respiratory syncytial virus.
Immunocompromised classification and respiratory co-infection (any) were
removed from the multivariate model due to multicollinearity with other pre-
dictive variables.
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Interestingly, identification of multiple respiratory viruses was
also associated with increased mortality. A potential expla-
nation for this finding is that host characteristics enabling
infection of multiple respiratory viruses may lead to worse
outcomes. This finding may be a surrogate marker for immu-
nocompromise or debilitation status of such patients and thus,
their increased risk of death. However, it is also possible that co-
infection with multiple viruses leads to a more pathogenic or
detrimental respiratory process.
Bacterial co-infection was not found to be associated with
in-hospital mortality in this study. Choi et al previously found
no difference in 28-day mortality between ICU patients with
severe bacterial or viral pneumonia at 25.5% and 26.5%,
respectively.30 There was no pure bacterial pneumonia com-
parator group in our study and so no direct comparison in
outcomes can be made between viral and bacterial pneumonia.
Our results do suggest that clinical outcomes of viral pneumonia
may not be substantially impacted by the presence of co-
infecting bacteria. However, antibacterial therapy in this popu-
lation was not thoroughly evaluated for appropriateness which
would likely impact clinical outcomes of patients with a
bacterial RCI.
Bacterial RCI occurred in 16.9% of patients with S. aureus
and streptococci being the most commonly identified organ-
isms. In a prospective study of mechanically ventilated patients
with severe community-acquired pneumonia by Karhu et al, S.
pneumoniae was the most frequently identified co-infecting
bacterial pathogen (68.4%; n¼ 13) among patients with a mixed
viral-bacterial pneumonia.4 Additionally, this study found more
frequent bacterial co-infection with only 5 patients (11.1%)
having a pure viral infection compared to 19 (42.2%) with
mixed viral-bacterial infections. Our study was not limited to
community-acquired infections which may account for this
disparity; however, other studies have also reported lower rates
of bacterial co-infection.29,30 Additionally, it is unlikely that a
higher incidence of healthcare-related infections would explain
the lower rates of bacterial co-infection observed.
Several limitations of our study should be recognized.
First, the retrospective design did not allow for determination
of the cause of mortality. Furthermore, antibacterial adminis-
tration before respiratory culture obtainment was not evaluated
and could have impacted rates of bacterial RCI seen. Second,
patients transferred from an outside hospital may have had
additional infectious processes identified by cultures taken
outside of our hospital system. In such cases, co-infections
may have been missed and falsely decreased the rates observed.
Third, viral shedding may occur for several days to weeks after
initial respiratory virus infection especially among immuno-
compromised patients. Our study classified viral pneumonia
based on the index RVP report date and radiographic evidence
of pneumonia. It is possible that for some patients the initial
viral infection had occurred days before identification by RVP
and that a concomitant process was detected on imaging. In this
case, more bacterial RCIs would be classified as subsequent
infections. Fourth, all cases in this study occurred in a 20-month
period at a single institution. Viral epidemiology at this site and
during this timeframe may not be representative of all seasons
and locations. Finally, due to the constraints of the RVP used,
we may have not identified all possible viral infections such
as bocavirus.
Respiratory viruses continue to be frequently identified in
hospitalized patients as new technologies push diagnostic abil-
ities forward. This study describes hospitalized adult patients
with viral pneumonia and factors associated with in-hospital
mortality. Identification of multiple respiratory viruses and
several factors describing severity of illness were associated
with in-hospital mortality in a multivariate model. Recognition
of multiple viruses as a poor prognostic indicator is of interest.
With increased ability to recognize viral pathogens, this finding
could simply be the result of improved diagnostics. However, it
may also be indicative of host factors allowing for simultaneous
infection by multiple respiratory viruses. In this study, only
16.9% of patients with viral pneumonia had a bacterial RCI. Use
of antibacterials in this setting was not evaluated, but future
research should focus on the role of empiric antibacterial use in
patients with only viral infection identified. Additionally, pro-
calcitonin has been shown to be useful in differentiating viral
infections from bacterial and could prove useful in conjunction
with identification of a respiratory virus in this population.4,31,32
In conclusion, this study adds to the growing body of literature
regarding the epidemiology of viral pneumonia in adult patients
and illustrates the high morbidity and mortality associated with
viral pneumonia in adult patients. Additionally, this study
suggests that identification of multiple infecting respiratory
viruses is a negative prognostic indicator as illustrated by its
association with in-hospital mortality. Continued advances in
diagnostic technology have enabled more thorough evaluation
of respiratory infections. Further investigation into the role
viruses play in pneumonia may unclose more answers regarding
patient risk factors for and outcomes of viral pneumonia.
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